Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 197

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease

Hyman, Bradley T. · 2011 · Archives of Neurology

Abstract

O P T I M I S M A B O U T therapeutic interventions in Alzheimer disease is based largely on a growing confidence that we understand theunderlyingpathobiologyof the illness.Breakthroughs ingenetics ledtotheidentificationof3early-onset Alzheimer disease autosomal dominant genes, each of which affects the metabolism of the small -amyloid (A ) peptide. This peptide is the core component of senile plaques, 1 of the 2 major histopathological hallmarksof thedisease.Biochemical and molecular analyses ultimately led to the identification of the and -secretases, enzymes important in generating A , and innovative approachesaimedatclearingA , including immunotherapy, have emerged. Giventhis intensive investigationinto the pathology of A , and the emergence of pharmacological targets directly relatedtoA metabolism,hope was strong that effectivewaysofhaltingor reversing thediseasewerenear at hand. However, a series of disappointing results from large clinical trials have ensued. Perhaps it would havebeenunrealistictoexpectthefirst generation of pharmacologic agents to be blockbusters, but even modest signals of clinical efficacy have been elusive.Thefirstactive immunization program was halted because of meningealencephalitis inasmallpercentage of the patients, but long followup of patients who were in the trial to autopsy showed no clear change in clinical course despite dramatic clearance of amyloid. In a more recent failure, the development of a -secretase inhibitor was halted because of systemic adverse effects, as wellasbecausepatients’cognitionnot only did not improve, but apparently got worse. Whatwentwrongwiththeserecent clinical trials? Is the “A hypothesis” in need of revision? The strong case from genetics and the fact that all patientswithAlzheimerdiseasehave innumerable amyloid plaques in their brains and elevated levels of synaptotoxic soluble amyloid still make the strongestpossiblecasethatA isacritical factor in the disease. However, it hasbeenrecognizedforyearsthatthere arepoorclinicalpathological correlations between plaques and the extent of cognitive impairment in patients with Alzheimer disease, whereas the otherhistologic featuresofAlzheimer disease—neuronal loss, synaptic loss, and neurofibrillary tangles—tend to match up much better with clinical symptoms. I propose in this commentary that the amyloid hypothesis needs to be reformulated to posit a 2-stageprocess inwhichamyloid initiates a cascade of pathophysiologic consequences,which in turnbecome increasingly independentof the initiatingamyloid.Thisrevisedhypothesis wouldexplain theapparent lackofefficacyof targetingA after thedisease isestablishedandsupports thesearch for therapies aimed at downstream events thatare theproximatecauseof neurodegeneration and dementia. One of the pillars of this new formulationis theobservationthat innumerableindividualshaveaccumulated amyloid plaques in their brains but donothavedementia. Asmanyas 30% of cognitively normal individuals in their 70s have amyloid plaques by positron emission tomography scans. These data concur with previous autopsy studies that had highlighted the possibility that amyloid plaques could accumulate even in “normal” individuals. Moreover, the numberofamyloidplaques thataccumulate in the brain appears to reach a near maximal level by the time patients have clinically apparent symptomsofcognitiveimpairment. Inan autopsy-based cross-sectional study, we foundthat amyloiddepositionaccumulated prior to the development of cognitive impairment, and thereafter, the amount of amyloid in the brain was similar across a wide range ofclinical severity, remainingatanalmostflatplateau.Bycontrast,atrophy, neuronal loss,synaptic loss,andnumberof tangles increasewithseverityof illness (Figure 1). The first phase of the disease, in which we now suggest that soluble oligomeric and fibrillar A accumulates, leads to local disruptionoftheneuropil, lossofdendritic spines, remodeling of neurites, and inflammatory responses. The second phase would consist of the (further)developmentoftangles,neuronal loss, synaptic loss, and glial responses in limbicandassociationcortices, and ultimately throughout the corticalmantle,withneurodegeneration ultimately leading to end-stage organ failure. What would happen if the second phase of the disease proceeds somewhat independently of A ? Dementia in Alzheimer disease would then be envisioned to be similar to the symptoms that a patient who has had heart attacks may display due to congestiveheartfailure.Forthesepatients, lowering their cholesterol level for a fewmonthsorayearwillnot improve their performance on the treadmill. Therapeutic strategies may be necessary to improve the symptoms of organfailureotherthanprimaryprevention strategies aimed at lowering the riskofheart attacks.Medicinehas innumerableexamplesofconditionsthat evolve over time and in which the ultimate cause of disability and illness Author Affiliation: Department of Neurology, Massachusetts General Hospit

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/archneurol.2011.70

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 197

Metadata

Authors
Hyman, B. T.
Venue
Archives of Neurology
Published
2011-08-01
Volume
68
Issue
8
Pages
1062
ISSN
0003-9942 (ISSN-L)
OpenAlex
W2110424796
Cited by
197
References
14
FWCI
13.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease. https://app.cochat.ai/papers/10.1001/archneurol.2011.70
The paper
Hyman, B. T. (2011). Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease. Archives of Neurology. https://doi.org/10.1001/archneurol.2011.70

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.